Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milsaperidone as Adjunctive Therapy in Major Depressive Disorder
NCT06830044Phase 3Recruiting
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Mar 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Milsaperidone with Placebo (2 arms). Primary endpoint: Montgomery-Asberg Depression Rating Scale at 6 weeks. Started Mar 2025; status: recruiting.
02
Drugs
milsaperidone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06830044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06830044.